Skip to main content
Clinical Trials/NCT00889356
NCT00889356
Unknown
Phase 3

Phase III, Open Label, Randomized, Multicenter Study to Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, Compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream for the Treatment of Bacterial Vaginosis and Candidiasis Isolatedly or in Association (Mixed-Type Vaginosis)

Zodiac Produtos Farmaceuticos S.A.1 site in 1 country160 target enrollmentSeptember 2009

Overview

Phase
Phase 3
Intervention
Clindamycin 100mg and Ketoconazole 400mg
Conditions
Candidiasis
Sponsor
Zodiac Produtos Farmaceuticos S.A.
Enrollment
160
Locations
1
Primary Endpoint
Efficacy based on cure rate evaluated by clinical and laboratory criteria.
Last Updated
17 years ago

Overview

Brief Summary

The purpose of this study is to determine the Efficacy, Tolerability & Safety of Combination of Clindamycin 100mg and Ketoconazole 400mg in Vaginal Capsules, used for 7 consecutive days in patients with Mixed-Type Vaginosis compared to Combination of Tetracycline 100mg and Amphotericin B 50mg in Vaginal Cream.

Registry
clinicaltrials.gov
Start Date
September 2009
End Date
March 2010
Last Updated
17 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
Zodiac Produtos Farmaceuticos S.A.

Eligibility Criteria

Inclusion Criteria

  • Mixed-type vaginosis
  • Bacterial vaginosis
  • Candidiasis

Exclusion Criteria

  • Pregnancy
  • Vaginal bleeding
  • History of recurrent vaginosis

Arms & Interventions

Clindamycin 100mg and Ketoconazole 400mg

Intervention: Clindamycin 100mg and Ketoconazole 400mg

Tetracycline 100mg and Amphotericin B 50mg

Intervention: Tetracycline 100mg and Amphotericin B 50mg

Outcomes

Primary Outcomes

Efficacy based on cure rate evaluated by clinical and laboratory criteria.

Time Frame: 7 days

Secondary Outcomes

  • Tolerability based on adverse events reports and patient's information(7 days)
  • Safety based on adverse events reports and laboratory criterion(7 days)

Study Sites (1)

Loading locations...

Similar Trials